NDAOPHTHALMICOINTMENT
Approved
Jan 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aureomycin (chlortetracycline hydrochloride) is a tetracycline antibiotic ointment administered via ophthalmic route for eye infections and bacterial conjunctivitis. It was one of the first broad-spectrum antibiotics approved for topical ocular use, representing a foundational therapy in ophthalmology.
LOE Approaching
This mature product approaching loss of exclusivity faces moderate competitive pressure (30%) and likely operates with a lean, maintenance-focused team structure rather than growth-oriented staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Aureomycin offers limited career advancement opportunity given its legacy status, generic competition, and approaching loss of exclusivity. Roles are primarily operational and maintenance-focused, suited to candidates seeking stability rather than high-growth trajectory.
Brand ManagerProduct Manager
Worked on AUREOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.